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INTRODUCTION
Tuberculosis has proved to be a menace for the human population in general and 
to the developing countries in particular as a widely prevalent infectious disease. WHO 
has declared  that  Tuberculosis  is  a  global  emergency.  An effective control  has been 
achieved  by  the  widespread  use  of  anti  tuberculosis  drugs.  However,  despite  their 
efficacy, superadded problems have to be faced in terms of long duration of treatment, 
emergence of MDR strains and certain adverse effects ascribed to these drugs. Among 
these adverse effects hepatotoxicity is a well known complication of Anti Tuberculous 
Therapy (ATT).
 The severity ranges from alteration in liver enzymes, chronic active hepatitis and 
picture of acute hepatitis, occasionally complicated by acute liver failure carrying very 
high mortality unless transplanted. It is common with Isoniazid especially when given in 
combination  with  Rifampicin  and  Pyrazinamide.  Fifteen  to  20  percent  of  patients 
receiving Isoniazid  as  a  single  agent  for  prophylaxis  against  tuberculosis  may  have 
increased serum alanine  and aspartate  aminotransferase  levels,  but  only  one  percent 
develop  hepatic  necrosis  severe  enough  to  require  the  withdrawal  of  the  drug. The 
clinical,  biochemical  and  histopathological  features  of  drug  induced  hepatotoxicity 
(DIH) are indistinguishable from that of viral hepatitis. 
Early  identification  and  modification  of  treatment  regimen  are  required  for 
patients who are at increased risk of anti tuberculous drug induced hepatotoxicity and 
hence reducing the morbidity and mortality. 
Reported  risk  factors  for  hepatotoxicity  include:  older  age,  female  sex,  poor 
nutritional  status,  high  alcohol  intake,  pre-existing  liver  disease,  HIV  co-infection, 
hepatitis  B  carriage,  increased  prevalence  of  viral  hepatitis  in  developing  countries, 
hypoalbuminaemia,  advanced  tuberculosis,  inappropriate  use  of  drugs  and acetylator 
status. 
Despite the above known risk factors, there is a subset of patients who develop 
fulminant hepatic failure as an idiosyncratic reaction to isoniazid.
 There has been an increase in the incidence of hepatotoxicity in the short course 
regimen followed by the RNTCP but exact incidence in our population is not known.
REVIEW OF LITERATURE
TUBERCULOSIS
DEFINITION
Tuberculosis  is  a  bacterial  infection  caused  by  the  acid  fast  bacillus 
Mycobacterium tuberculosis. The principal lesions are found in the lungs although other 
organs like lymph nodes, abdomen, meninges, bones and joints could be involved by 
dissemination.  The  major  portal  of  entry  is  by  droplet  inhalation  except  in  bovine 
tuberculosis where the organism enters by the oral route.
Tuberculosis affects humans in mainly two forms
Primary TB: is common among children and usually not transmissible
Secondary (postprimary) TB: happens in adults which is often infectious
PATHOGENESIS
This is determined by both the bacterial and host factors. The tubercle bacillus has three 
important factors which distinguish it from other organisms and help in the pathogenetic 
process:
1. Slow generation time
2. Lack of exotoxin or endotoxin
3. High lipid content of bacillus1
PHARMACOTHERAPY OF TUBERCULOSIS
For many years, the only drug used to treat tuberculosis was isoniazid and the 
duration of  therapy was nearly 18 months.  In  1972,  Wallace fox and his  colleagues 
showed  that  the  addition  of  rifampicin,  and  pyrazinamide  to  regimens  containing 
isoniazid made it possible to reduce the duration of treatment.
Advantages of the short course regimen include rapid bacteriological conversion, 
lower  failure  rates,  better  patient  compliance  and  reduction  in  the  frequency  of 
emergence of drug resistant bacilli, the only disadvantage being the high cost.
There are now a number of short course regimens of six months duration which 
are highly effective, less toxic and well tolerated. The regimens used under the Revised 
National Tuberculosis Control Program (RNTCP) are shown in table 1.2
TABLE 1: CATEGORIES OF ATT UNDER RNTCP
Category Type of patient Regimen
Category I  New sputum positive
 Seriously ill** sputum 
negative
 Extra  pulmonary 
seriously ill
2(HRZE)3 + 4(HR)3
Category II Sputum  positive 
default,  failure  and 
relapse,others***
2(HRZES)3+ 
1(HRZE)3 + 5(HRE)3
Category III Sputum  negative  not 
seriously ill
Extra  pulmonary  not 
seriously ill
2(HRZ)3 + 4(HR)3
 The numbers before the letters denote the number of months of treatment.
 The subscript after the letters denotes number of doses per week.
 The strengths of the drugs are as follows: isoniazid (H)-600mg, rifampicin(R)-450mg, 
Ethambutol (E)-1200mg, pyrazinamide (Z)-1500mg, streptomycin(S)-750mg.
Patients who weigh 60kg or more receive additional 150mg rifampicin.
Patients who are more than 50yrs receive 500mg streptomycin.
Patients who weigh < 30kg receive drugs as per body weight.
Patients in category I and II who remain sputum positive at the end of the intensive 
phase are given one more month of intensive therapy.
Patients in categories I and II who have positive sputum smear at the end of the initial 
intensive phase receive an additional month of intensive phase treatment.
** Seriously ill also includes, any patient, pulmonary or extra pulmonary who is HIV 
positive 
***In exceptional cases, patients who are sputum smear negative or extra pulmonary 
can have relapse or failure and categorized as, “others”
 Examples  of  extra  pulmonary  seriously  ill  include  meningitis,  pericarditis, 
disseminated tuberculosis, peritoneal, genitourinary tuberculosis and spinal tuberculosis 
with neurological complications. 3
CLASSIFICATION OF ANTITUBECULAR AGENTS
Traditionally anti TB agents have been classified into first line and second line 
agents as follows:
First line essential: isoniazid, rifampicin, pyrazinamide.
First line supplementary: ethambutol and streptomycin.
Second line: older agents (paraaminosalicylic acid, ethionamide and cycloserine), newer 
agent  (rifapentine),  kanamycin,  amikacin,  capreomycin  and  newer  quinolones  like 
gatifloxacin and moxifloxacin.1
TABLE 2: SIDE EFFECTS OF ANTI TB DRUGS
Isoniazid Common Anorexia, nausea, vomiting, fever
Rare Rash,  peripheral  neuropathy,  hepatotoxicity, 
optic neuritis, hyperglycemia, hemolytic anemia
Rifampicin Common Orange  coloration  of  urine,  nausea,  diarrhea, 
rash
Rare Hepatotoxicity,  flu  like syndrome (intermittent 
regimen),  thrombocytopenia,  interstitial 
nephritis, menstrual disturbances
Pyrazinamide Common Nausea, vomiting, fever
Uncommon Hepatitis, urticaria, skin rash, arthralgia
Rare Photosensitivity,  gout,  sideroblastic  anemia, 
aggravation of peptic ulcer
Ethambutol Common Optic neuritis, arthralgia, color blindness 
Rare Hepatitis,  interstitial  nephritis,  cutaneous 
reaction
Streptomycin Common Vertigo,  tinnitus,  cutaneous  hypersensitivity, 
deafness
Rare Renal  damage,  agranulocytopenia,  aplastic 
anemia, neuromuscular blocking action1
ISONIAZID
Isoniazid is still considered the main drug in any anti TB regimen. Its primary 
mechanism of action is inhibition of synthesis of mycolic acids which are important 
constituents of the bacterial cell wall. 90% of the drug is excreted within 24 hours in the 
urine  and  the  excretory  products  are  mainly  due  to  acetylation.  The  acetylation  is 
significantly altered by the acetylator status of the individual. The status is measured by 
estimating free  and total  sulfa  dimidine  in  blood and urine.  Several  risk  factors  for 
isoniazid  toxicity  have  been  identified  which  include  acetylator  status,  old  age, 
alcoholism and malnutrition. Jaundice occurs in 0.6% to 1% of patients whereas enzyme 
increase occurs in 10-20% of the patients. 
RIFAMPICIN
Rifampicin  inhibits  DNA dependent  RNA polymerase of  mycobacterium.  It  is 
bactericidal for both intracellular and extra cellular organisms and is widely distributed 
in  all  body  fluids  including  CSF.  Hepatotoxicity  from  rifampicin  rarely  occurs  in 
patients with normal liver function. Risk factors include old age, chronic liver disease 
and  alcoholism.  Increase  in  bilirubin  and  alkaline  phosphatase  are  characteristic  of 
rifampicin toxicity. Clinical hepatitis occurs in 0.6% to 2% whereas enzyme increase 
occurs in 5-10%. One Indian study shows an incidence of jaundice of 7-8%. Toxicity 
appears to be enhanced by the addition of isoniazid.
PYRAZINAMIDE
It  is  a  synthetic  pyrazine  derivative  of  nicotinamide.  Target  appears  to  be 
mycobacterial mycolic acid I gene which is involved in mycolic acid synthesis. When a 
dose of 40-50mg/kg is administered orally, hepatotoxicity is seen in 15% of patients and 
jaundice in 2-3%. Recent regimens are much safer as they employ lower doses. A large 
Indian study showed that in regimens containing isoniazid, rifampicin and pyrazinamide, 
there was no additional hepatoxicity contributed by pyrazinamide.
ETHAMBUTOL
It is a bacteriostatic drug with no reports of hepatotoxicity. Three fourths of the 
ingested dose is excreted unchanged through the kidneys.
BACTERIAL POPULATIONS AND ACTIONS OF DRUGS
A model  proposed  for  explaining the  early  bactericidal  and special  sterilizing 
properties of drugs includes:
Population A: actively dividing organisms, killed mainly by INH.
Population  B:  semi  dormant  organisms  mainly  seen  in  acid  pH  inhibited  by 
pyrazinamide.
Population  C:  semi  dormant  organisms  with  spurts  of  activity  killed  mainly  by 
rifampicin.
Population D: completely dormant, unaffected by any drug.1
DRUG INDUCED LIVER INJURY
Drug-induced  liver  injury  (DILI)  has  been  a  long-standing  concern  in  the 
treatment of tuberculosis (TB) infection. The liver has a central role in drug metabolism 
and detoxification, and is consequently vulnerable to injury.4
Drug-induced liver injury (DILI) is ultimately a clinical diagnosis of exclusion. 
Other causes of liver injury, such as acute viral hepatitis, should be methodically sought 
and their  absence makes the diagnosis plausible.  Usually,  the time of onset  to acute 
injury is within months of initiating a drug. Rechallenge with the suspected offending 
agent  with  more  than  twofold  serum alanine  aminotransferase  (ALT)  elevation  and 
discontinuation leading to a fall in ALT, is the strongest confirmation of the diagnosis. 
Rechallenge may, in some instances,  endanger the patient and is usually confined to 
essential  drugs  or  used  when  multiple  potentially  hepatotoxic  drugs  have  been 
administered concomitantly. 
DILI may result from direct toxicity of the primary compound, a metabolite, or 
from an immunologically  mediated  response,  affecting hepatocytes,  biliary  epithelial 
cells  and/or  liver  vasculature.  In  many  cases,  the  exact  mechanism  and  factors 
contributing to liver toxicity remain poorly understood.
The two major classes of DILI are the predictable and unpredictable responses. 
Predictable  DILI  is  generally  characterized  by  certain  dose-related  injury  in 
experimental  animal  models,  has  a  higher  attack  rate  and  tends  to  occur  rapidly. 
Injurious  free  radicals  cause  hepatocyte  necrosis  in  zones  farthest  from the  hepatic 
arterioles, where metabolism is greatest and antioxidant detoxifying capacity is the least.
Unpredictable  or  idiosyncratic  reactions  comprise  most  types  of  DILI.  These 
hypersensitivity or metabolic reactions occur largely independent of dose and relatively 
rarely  for  each  drug,  and  may  result  in  hepatocellular  injury  and/or  cholestasis. 
Hepatocyte necrosis is  often distributed throughout hepatic lobules rather than being 
zonal, as is often seen with predictable DILI. In hypersensitivity reactions, immunogenic 
drug or its metabolites may be free or covalently bound to hepatic proteins, forming 
haptens  or  neoantigens.  Antibody-dependent  cytotoxic,  T-cell  and  occasionally 
eosinophilic hypersensitivity responses may be evoked. Released tumor necrosis factor 
(TNF),  interleukin  (IL)-12  and  IFN  promote  hepatocellular  programmed  cell  death 
(apoptosis), an effect opposed by IL 4, IL-10, IL-13, and monocyte chemotactic protein-
1.
Metabolic idiosyncratic reactions may result from genetic or acquired variations 
in drug biotransformation pathways, with synthesis or abnormally slow detoxification of 
a hepatotoxic metabolite. Metabolic idiosyncratic reactions may have a widely variable 
latent period, but recur within days to weeks after re-exposure.
Types of DILI
A variety of clinical syndromes may be seen with DILI, even with a single drug.5
Hepatic adaptation
Exposure  to  certain  drugs  may  evoke  physiologic  adaptive  responses.  The 
induction of survival genes, including those that regulate antioxidant, anti-inflammatory 
and antiapoptotic pathways, may attenuate toxin-related injurious responses. Such injury 
may also stimulate hepatocyte proliferation and protective adaptation. Asymptomatic, 
transient  elevations  of  ALT may  reflect  slight,  nonprogressive  injury  to  hepatocyte 
mitochondria,  cell  membranes  or  other  structures.  Such  injury  rarely  leads  to 
inflammation, cell death or significant histopathologic changes. The induction of hepatic 
microsomal  (cytochrome  P450)  enzymes,  capable  of  metabolizing  the  inducing 
medication, is another form of hepatic adaptation.
Drug-induced acute hepatitis or hepatocellular injury 
A  transaminase  threshold  for  clinicopathologically  significant  drug-induced 
hepatitis  has not  been systematically determined for  most  medications.  Patients  with 
acute hepatocellular injury may be asymptomatic or may report a prodrome of fever and 
constitutional  symptoms,  followed  by  nausea,  vomiting,  anorexia  and  lethargy. 
Histopathology  may  reveal  focal  hepatic  necrosis,  with  bridging  in  severe  cases. 
Markedly  increased  transaminase  concentrations  followed  by  jaundice  imply  severe 
liver disease with a 10% possibility of fulminant failure, as said by the late hepatologist  
and DILI expert Hyman Zimmerman. Coagulopathy may develop 24 to 36 hours after 
onset, although this can subsequently resolve. Coagulopathy persisting beyond 4 days is 
a poor prognostic sign in acetaminophen-related hepatotoxicity.
Nonalcoholic fatty liver disease
Steatosis  or  simple  fatty  liver  is  most  commonly  caused  by  obesity,  insulin 
resistance  and  probably  alterations  in  triglyceride  metabolism.  Ethanol,  steroids  and 
highly active antiretroviral therapy (HAART) are associated with the development and 
exacerbation  of  non  alcoholic  fatty  liver  disease.  Constitutional  symptoms, nausea, 
vomiting or abdominal pain are uncommon. Laboratory findings in severe cases include 
hypoglycemia,  increased  serum transaminase  concentrations,  prolonged  coagulation 
time and metabolic acidosis. Most instances of drug-induced steatosis are reversible, if 
the offending agent is stopped. Persistent steatotic injury may progress to steatohepatitis, 
characterized histopathologically  by hepatic  inflammation,  fatty  infiltration and by a 
subsequently higher risk of cirrhosis.
Granulomatous hepatitis
Granulomata  are  common,  nonspecific  findings  in  liver  histology  and  are 
potentially related to infectious, inflammatory or neoplastic etiologies. Hypersensitivity 
reactions to drugs, such as allopurinol, quinidine, sulfonamides and pyrazinamide are a 
common cause of this type of lesion. Patients may have fever, lethargy, myalgias, rash, 
lymphadenopathy,  hepatosplenomegaly  with  increased  serum ALT concentration  and 
even vasculitis.
Cholestasis
Bland  cholestasis,  typically  reported  with  estrogen  treatment,  consists  of 
asymptomatic, usually reversible increases in serum alkaline phosphatase and bilirubin 
concentration caused by a failure of bilirubin transport. There is a lack of inflammation 
in liver tissue.
Chemical cofactors for DILI
Ethanol induces cytochrome P450 2E1, which promotes metabolism of ethanol 
itself,  acetaminophen  and  others.  Ethanol  metabolism  yields  acetaldehyde,  which 
contributes  to  glutathione  depletion,  protein  conjugation,  free  radical  generation  and 
lipid  peroxidation.  Chronic  ethanol  abuse  activates  hepatic  collagen-producing 
sinusoidal (stellate) cells, potentially contributing to fibrosis. 
Pre-existing liver disease
Abnormal baseline transaminases are an independent risk factor for DILI. Patients 
with HIV and hepatitis C however, appear to have increased frequency of antiretroviral 
medication related DILI. The severity of DILI, when it occurs, may be greater in patients 
with underlying liver disease, likely reflecting a summation of injuries.
Clinical syndromes associated with Drug induced hepatotoxicity include:
1. Liver enzyme elevation in asymptomatic patients
2. Acute viral hepatitis like picture
3. Fulminant hepatic failure
4. Sub acute hepatic failure
5. Cholestatic hepatitis
6. Acute hepatic venous outflow obstruction
7. Autoimmune hepatitis like picture
8. Chronic hepatitis
9. Cirrhosis.6
MECHANISM OF HEPATOTOXICITY DUE TO ANTI TB AGENTS
ISONIAZID
Reactive  metabolites  of  MAH  (mono  acetyl  hydrazine)  are  probably  toxic  to 
tissues through free radical generation. The antioxidant N-acetyl-cysteine, a substrate for 
glutathione  synthesis,  inhibits  isoniazid-induced  liver  injury  in  pretreated  rats,  with 
unknown relevance in humans.
   Additional metabolic idiosyncratic mechanisms appear to be operative. Slow 
acetylators  appear  to  be  particularly  susceptible  to  hepatotoxicity.  The  isoniazid 
metabolite  acetyl-hydrazine  covalently  binds  to  liver  macromolecules,  a  process 
mediated by microsomal enzymes. The exact mechanism is still elusive.1
RIFAMPICIN
Conjugated  hyperbilirubinemia  probably  is  caused  by  rifampin  inhibiting  the 
major bile salt exporter pump. Asymptomatic elevation of bilirubin may also result from 
dose-dependent competition with bilirubin for clearance at the sinusoidal membrane or 
from impeded secretion at the canalicular level. Rare hepatocellular injury appears to be 
a hypersensitivity reaction and it may be more common with large, intermittent doses. 
Hypersensitivity reactions have been reported in combination with renal dysfunction, 
hemolytic anemia or flu like syndrome. Studies have proved that rifampicin induced 
hepatitis  occurs  earlier  than  isoniazid.  There  is  also  evidence  that  the  addition  of 
rifampicin to isoniazid causes enzyme induction and enhanced production of its toxic 
metabolites. 
PYRAZINAMIDE
Pyrazinamide  may  exhibit  dose  dependent  and  idiosyncratic  hepatotoxicity. 
Several decades ago, daily doses of pyrazinamide at 40 to 50 mg/kg commonly caused 
hepatotoxicity, and a relationship to dose was noted. There may be shared mechanisms 
of injury for isoniazid and pyrazinamide, because there is some similarity in molecular 
structure.  Patients who previously had hepatotoxic reactions with isoniazid have had 
more  severe  reactions  with  rifampin  and  pyrazinamide  given  for  latent  tuberculosis 
infection.  Pyrazinamide  may  induce  hypersensitivity  reactions  with  eosinophilia  and 
liver injury or granulomatous hepatitis.
RIFABUTIN
At the usual doses (150-200 mg/day), hepatotoxicity is uncommon. There is less 
induction of hepatic microsomal enzymes than with rifampin. Elevated transaminases 
have been reported with high-dose (600 mg/day) rifabutin treatment in combination with 
macrolides.
HEPATOTOXICITY DURING TREATMENT OF TB
 Overall, the risk of TB DILI in various studies ranges from 5% to as high as 33%. 
The possible risk factors for TB DILI are discussed subsequently.5
Age over 35
Several studies suggest that increasing age is a risk factor for TB DILI, but often 
statistical significance was not achieved or hepatotoxicity was not treatment limiting. 
One study reported a TB DILI rate ranging from 2 to 8% as age increased, with an 
average of 5%.Other studies have reported that hepatotoxicity ranges from 22 to 33%in 
those older than 35 years, compared with 8 to 17% in those younger than 35 years.7
Children
There are varied reports of increased hepatotoxicity amongst children treated with 
anti TB therapy which was especially high in children with neurotuberculosis.8
Sex
For women, several studies report increased risk of hepatotoxicity, but this was 
not always treatment limiting, or did not achieve statistical significance. One study did 
show a four times higher risk of treatment limiting hepatotoxicity in women, but with an 
overall incidence of only 2%. Two other studies showed no increased risk in women.9
Cofactors
Several studies have indicated that alcohol use was a significant predictor of TB 
DILI, whereas two studies found no association.10
Abnormal Baseline Transaminases
One  study  found  an  increased  risk  of  hepatotoxicity  during  treatment  of  TB 
disease in individuals with abnormal baseline transaminases.11
Acetylator Status
When acetylation rate has been determined by phenotypic assays, slow acetylators 
have experienced more hepatotoxicity in some studies but not in others.
Other Factors
Malnutrition or hypoalbuminemia was associated with TB DILI in several studies 
from India.12  The presence of HLA-DQB1*0201 is an independent risk factor for the 
development of TB DILI.13 Gene polymorphisms at loci of genes coding for cytochrome 
P4502E1  and  for  glutathione  S-transferase  have  also  been  associated  with 
hepatotoxicity.14
Disease severity
Extensive  TB  disease  itself  may  be  a  risk  factor  for  TB  DILI,  although 
confounding  factors  are  impossible  to  exclude.12 Liver  transplant  patients  with  TB 
appear to have a high rate of hepatotoxicity, with five of six treated patients developing 
this complication, confirmed by liver biopsy and three of six suffering graft rejection.
Regimen
In a meta-analysis, the presence of rifampicin in a multidrug treatment regimen 
increased the incidence of significant hepatotoxicity for adults from 1.6 to 2.55% and in 
children from 1.0 to 6.9%.15 The influence of pyrazinamide on TB DILI is ambiguous; 
some studies indicate little to no increased rate of hepatotoxicity, whereas others point to 
it as a contributor to increased incidence or severity of hepatotoxicity, although dosing 
variations and patient selection biases may have contributed to these results.
HIV-infected Individuals
In a Western European clinical trial enrolling patients with TB-AIDS from 1989 
to 1994, many who used intravenous drugs, 13 to 15% of patients had transaminase 
increases  of  at  least  three  times  the  ULN in  the  first  2  months.  Hepatoxicity  was 
attributed to isoniazid in 55%of those with hepatitis. In a study of HIV, hepatitis C and 
TB  treatment,  HIV  infection  independently  increased  the  risk  fourfold  of  serum 
transaminase  increase  to  120  IU/L  or  of  total  bilirubin  to  at  least  1.5  mg/dl. 
Approximately  27%of  HIV infected  individuals  developed  hepatotoxicity,  compared 
with 12% among HIV-uninfected individuals. Nearly 80% of the patients in this study 
had a history of alcohol abuse, although random testing did not reveal active drinking, 
patients had not consumed alcohol in the 10 days before study entry, and all had normal 
baseline hepatic transaminases.16 
Hepatitis B
Several studies from Asia have addressed DILI during treatment of TB disease in 
patients with hepatitis B infection. Additional studies are needed, but the limited data 
leave sufficient concern that hepatitis B maybe a risk factor for more frequent or severe 
hepatotoxicity during treatment of TB disease.
Hepatitis C
Hepatitis C was an independent risk factor for the development of hepatotoxicity, 
elevating the risk fivefold of transaminase elevation of at least 120 U/L, or of serum 
bilirubin of at least 1.5 mg/dl. Co infection with both hepatitis C and HIV elevated the 
risk of hepatotoxicity more than 14-fold.
DILI with Second-line Anti-TB Agents
Hepatotoxicity has been recognized to occur in about 2% of patients treated with 
ethionamide or prothionamide and in 0.3% of patients treated with para-aminosalicylic 
acid17, 18. Cycloserine does not appear to be associated with hepatotoxicity, but should be 
used with caution in patients at risk for alcohol withdrawal seizures. 
Singh et al19 reported an overall mortality of 12% in patients with ATT induced 
hepatotoxicity while it was 75% in patients with acute and sub acute liver failure.
In  a  case  control  study  from AIIMS  New  Delhi,  Pande  et  al20 proposed  the 
following diagnostic criteria for ATT induced hepatotoxicity-
1. Symptoms and signs of icteric hepatitis (anorexia, nausea, jaundice)
2.  Rise in liver  transaminases to more than 3 times the upper limit  of  normal  on 3 
occasions or a single value of >250IU/L.
3. Increase in serum bilirubin >1.5mg/dl
4. Absence of serological evidence of viral hepatitis.
In  a  retrospective  study  of  519  patients  in  Germany  receiving  isoniazid, 
rifampicin and pyrazinamide, hepatotoxicity was observed in 11% of patients9.
In another study of 456 patients from Argentina receiving all 5 first line drugs, 
liver injury was seen in 9.9% of patients21.
MANAGEMENT OF TB DILI
Pretreatment Clinical Evaluation
1.  A  standardized  history  form  is  recommended,  which  includes  risk  factors  for 
hepatotoxicity.
2. The physical examination should include evaluation for signs of liver disease, such as 
liver tenderness, hepatosplenomegaly, jaundice, caput medusa, spider angiomata, ascites, 
and edema.
3. Previous laboratory values should be reviewed when available.
4. Screening for viral hepatitis should be considered for the following patients
- Individuals who inject drugs; 
- were born in endemic areas of Asia, Africa, the Pacific Islands,   Eastern Europe, 
or the Amazon Basin; 
- are HIV infected; 
- may have had sexual or household contact with chronically infected individuals;
- may have had occupational exposure to infected blood;
- are chronic hemodialysis patients;
- are recipients of clotting factors before 1987;
- have undiagnosed liver disease
5.  Voluntary  HIV counseling  and testing are  recommended for  all  patients  with TB 
disease.5
Patient Education
1.  Printed  instructions  should  include  clinic  telephone  numbers,  include  explicit 
instructions for  after-hours  care,  and utilize  patient  preferred language at  a  readable 
level.
2.  Patients  should  be categorically  told to  immediately  stop medications  for  nausea, 
vomiting,  abdominal  discomfort,  or unexplained fatigue and to contact  the clinic for 
further evaluation.
3.  Patients should attend clinic follow-up visits  for  monitoring and reinforcement of 
education.
4.  Patients  should  be  warned  about  concomitant  alcohol  and  hepatotoxic  over-the-
counter, and alternative and prescription medication use.
5. Patients should inform their health care providers of anti-TB medications prescribed 
drug adverse events.
Baseline laboratory testing and monitoring:
1.  Baseline  measurements  of  serum  transaminases,  bilirubin,  alkaline  phosphatase, 
creatinine and a blood platelet count are recommended for all adults beginning treatment 
for TB disease.
2. For patients with preexisting severe liver disease, some clinicians also recommend 
periodic measurement of prothrombin time and INR to assess hepatic synthetic function.
3.  Routine  measurements  during  treatment  are  recommended  when  baseline 
abnormalities are present and for patients, who chronically consume alcohol, take other 
potentially  hepatotoxic  medications  or  who  have  viral  hepatitis  or  history  of  liver 
disease, HIV infection or prior TB DILI.
4. In patients with abnormal baseline transaminases, the range of their prior fluctuations 
may be of assistance in interpreting results of biochemical monitoring of treatment.
5. Some providers prefer to monitor ALT in women or older adults being treated for TB 
disease
7. ALT is preferred for detecting and tracking hepatocellular injury in those who develop 
symptoms of hepatotoxicity.
8.  Measurements  of  AST,  bilirubin  and  alkaline  phosphatase  are  adjunctive  for 
monitoring chronic liver disease, cholestasis or severe hepatocellular injury.
9. The ULN used should be that of the laboratory performing the assay.
10. Optimally, reference limits for enzymes should be adjusted for age in children and in 
adults older than 60 and for sex in adults, if available.
11. Hepatitis B surface antigen seropositive individuals with elevated ALT should have 
HBeAg testing. If positive,  rifampin may be preferred over isoniazid. A hepatologist 
should be consulted regarding further testing and possible pretreatment in individuals 
with an ALT at least two times the ULN and who are HBeAg seropositive. In HBeAg-
seropositive individuals, clinical and ALT monitoring should occur every 2 to 4 weeks.
12. Patients with baseline transaminases more than three times the ULN should have 
ALT retested  along with bilirubin,  as  well  as  screening for  viral  or  other  causes  of 
hepatitis, including alcohol and hepatotoxic drugs. 
Treatment of TB Disease
Regimen selection
The crucial efficacy of isoniazid and particularly rifampin warrants their use and 
retention,  if  at  all  possible,  even  in  the  face  of  preexisting  liver  disease.  Several 
regimens are recommended if baseline serum ALT is more than three times the ULN and 
TB is not believed to be the cause.
1. Treatment without pyrazinamide might utilize isoniazid and rifampin for 9 months 
with  ethambutol  until  drug  susceptibility  testing  of  the  M.tuberculosis isolate  is 
completed.
2.  In  patients  with  cirrhosis,  rifampin,  Ethambutol  and  treatment  with  levofloxacin, 
moxifloxacin, gatifloxacin or cycloserine for 12 to 18 months may be considered.
3.  For  patients  with  encephalopathic  liver  disease,  Ethambutol  combined  with  a 
fluoroquinolone, cycloserine and capreomycin or aminoglycoside for 18 to 24 months 
may be an option. However, these regimens have not been tested systematically.
4.  Some  providers  avoid  aminoglycosides  in  severe,  unstable  liver  disease  due  to 
concerns about renal insufficiency or bleeding from injected medication in patients with 
thrombocytopenia and/or coagulopathy.
Interventions for hepatotoxicity.
The first-line anti-TB drugs, especially rifampin, should not be discontinued for 
mild gastrointestinal complaints, which may be relatively frequent in the initial weeks of 
anti-TB treatment. If serum transaminase concentrations are more than five times the 
ULN (with or without symptoms)or more than three times the ULN with jaundice and/or 
hepatitis  symptoms,  then  potentially  hepatotoxic  medications  should  be  stopped 
immediately and the patient evaluated promptly. Serologic tests for hepatitis A, B, C and 
E viruses should be obtained, and the patient should be evaluated for biliary disease, use 
of alcohol and other hepatotoxic drugs. Some experts recommend interrupting treatment 
for lesser increases in patients with cirrhosis or encephalopathy. Until the specific cause 
of abnormalities can be determined, clinicians should treat with at least three anti-TB 
agents that are less likely to cause hepatotoxicity namely streptomycin, Ethambutol and 
quinolones.
Rechallenge
The risk of reintroducing of a TB medication could be hazardous and should be 
considered relative to its potential benefit. Rechallenge is considered when it is unclear 
which  medication  was  the  cause  of  symptoms  or  of  transaminases  increases. 
Rechallenge also may be considered if an increase in transaminases concentration did 
not reach the usual treatment limiting threshold. Rechallenged patients who had reached 
a treatment limiting threshold should have clinical and biochemical monitoring at 2-to 4-
week  intervals.  Rechallenged  patients  should  be  told  to  stop  medication  in  case  of 
hepatitis symptoms. 
After  the  enzymes  return  to  normal,  the  drugs  are  introduced  sequentially. 
Isoniazid is introduced first at a dose of 50mg/day and increased to 300mg/day over the 
next 2-3 days if well tolerated.2 
Rifampicin is introduced after another 3-4 days at doses of 75mg/day and increase 
to full  dose over a period of 3-4 days. Pyrazinamide is introduced next at a dose of 
250mg, increasing to 1000mg over the next few days.
Studies show that the recurrence of hepatotoxicity is very less after reintroduction 
of  ATT. Singh et  al  reported  a  recurrence rate  of  6.8% in their  study.  Telman et  al 
reported a recurrence rate of 6.3%.11
 A high recurrence rate was noted in one study in Copenhagen10 (26%). Further 
multicentric studies are needed to clarify these issues.
AIMS AND OBJECTIVES
The aim of the study is to analyze the following-
1.  To  study  the  incidence  of  hepatotoxicity  in  patients  taking  antituberculous  drug 
therapy under the RNTCP short course schedule in Madurai district
2. To analyze the various risk factors for development of hepatotoxicity.
MATERIALS AND METHODS
THE STUDY GROUP
The study was conducted on patients coming to the chest clinic in Govt. Rajaji 
hospital,  Madurai.  Approval  from ethical  committee  was obtained.  The study was a 
prospective study conducted for a period of one year between June 2007-2008.
The inclusion criteria were-
1.  Patients  prescribed  to  receive  ATT for  confirmed  pulmonary  or  extra  pulmonary 
tuberculosis under the RNTCP schedule.
2. Patients coming from in and around Madurai city, to minimize the rate of dropouts. 
The exclusion criteria were-
1. Patients not receiving isoniazid or rifampicin as a part of therapy.
2. Patients with preexisting acute or chronic liver disease.
3. Patients with fatty liver as diagnosed by ultrasound examination of the abdomen.
4. Baseline transaminases more than twice the upper limit of normal.
5. Chronic alcohol intake.
6. Patients with previous history of hepatotoxicity due to ATT.
METHODS
All the patients had pretreatment evaluation clinically especially for evidence of 
liver disease, history of alcoholism or concomitant drug therapy and systemic illness in a 
prepared proforma, a copy of which is annexed. Baseline laboratory evaluation was done 
for all patients which included hemoglobin levels, serum albumin, liver function tests 
and  ultra  sonogram of  the  abdomen  and  HIV status.  Body  mass  index  (BMI)  was 
calculated as follows2-
BMI = weight (kg)/height (metre2)
Malnutrition - <18.5kg/m2
Normal – 18.5-24.9kg/m2
Obese - > 25kg/m2 
Normal values for LFT were as follows-
Serum albumin >3.5grams/dl – normal
Serum albumin <3.5grams/dl – hypoalbuminemia
Serum bilirubin 0.2-0.8 mg%--normal
AST 15-40 iu/l--normal
ALT 15-40 iu/l--normal
Anemia was defined as the hemoglobin of less than 13 g/dl in males and less than 12 
g/dl in females.22
Mild anemia was defined as hemoglobin level of 10-12.9 g/dL in males and 10-
11.9 g/dL in females, moderate anemia was defined as hemoglobin level of 7-9.9 g/dL 
and severe anemia was defined as hemoglobin level  of  less than 7g/dL both among 
males and females.22, 23
Viral markers were done to exclude chronic viral hepatitis at the start of therapy. 
Presence of fatty liver was excluded on the basis of ultrasonography.
The patients were categorized into various regimens in RNTCP according to the 
type of disease, the details of which were explained previously.
Doses of the drugs were as follows-
Isoniazid-600mg
Rifampicin-450mg (600mg if >60kg)
Pyrazinamide-1500mg
Ethambutol- 1200mg
Every effort was taken to maintain compliance to the drug therapy.
Patients were informed about the side effects of medications and were asked to 
report  immediately  if  they  developed  any  of  these  symptoms.  Patients  with  minor 
symptoms were  treated  symptomatically.  Those  with  major  symptoms  suggestive  of 
hepatotoxicity were hospitalized and evaluated.
Diagnosis of Drug Induced Hepatotoxicity:   
Hepatotoxicity was defined as the presence of at least one of the following criteria: 
(1) Appearance of jaundice.
 (2) a rise of at least five times the upper limit of normal levels (40 IU/L) of serum 
aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) or >250IU/L 
on any one occasion without symptoms or more than three times ULN with symptoms. 
(3) A rise in the level of serum total bilirubin > 1.5mg/dl.24
Liver  enzymes  (AST/ALT)  were  estimated  using  the  UV kinetic  International 
Federation of Clinical Chemistry method.
 LFTs were repeated weekly for the first month then at the end of second month 
and after the completion of ATT (six months). 
If the patients developed evidence of hepatotoxicity, viral markers (hepatitis A, B, 
C) were again performed to rule out acute viral hepatitis. 
The information collected  regarding all  the  selected  cases  were  recorded  in  a 
Master Chart. Data analysis was done with the help of computer using Epidemiological 
Information Package (EPI 2002).
Using  this  software,  frequencies,  percentages,  means,  standard  deviations,  chi 
square and ‘p’ values were calculated. Kruskul Wallis chi-square test was used to test the 
significance of difference between quantitative variables and Yate's test for qualitative 
variables. A 'p' value less than 0.05 is taken to denote significant relationship.
.
RESULTS AND ANALYSIS OF OBSERVED DATA
EPIDEMIOLOGY
The study group was divided into various age groups which ranged between 15 
and 78 years. A total of 166 patients were included in the study of which 156 patients 
were followed up till six months of treatment. Total number of dropouts from the study 
at the end of six months was 10 out of which seven patients dropped out at the end of 
two weeks and three at the end of three weeks. Most patients were from in and around 
Madurai city.
 The mean age of the population was 36.6+13.8 years. Out of 156 patients, 88 
were male (56.5%) and 68 were female (43.5%). Most of the patients were in the ages 
between 15 and 39 years (66%). 
TABLE 3: AGE DISTRIBUTION OF PATIENTS
Age(yrs) Male(M) Female(F) Total %
<30 30 22 52 33.3
30-39 27 24 51 32.7
40-49 15 11 26 16.7
50-59 9 6 15 9.6
>60 7 5 12 7.7
MEAN 36.6 yrs
S.D 13.8 yrs
SYMPTOMATOLOGY
There was a higher proportion of pulmonary tuberculosis (n=90) than the extra 
pulmonary  form  (n=66).  Pleural  effusion  was  the  most  common  form  of  extra 
pulmonary tuberculosis seen in 31 patients (19.9%) followed by neurotuberculosis in 16 
patients (10%).
TABLE 4: SITE OF DISEASE
Site M F Total %
Pulmonary 50 40 90 57.7
Pleural effusion 20 11 31 19.9
Lymph node 5 8 13 8.3
Abdominal 2 2 4 2.6
Skeletal 2 0 2 1.3
NeuroTB 9 7 16 10.2
Ninety  patients  were  registered  under  category  I  ATT (59%)  followed  by  52 
patients in category III (32%) and 14 patients in category II (9%) as shown in table- 5. 
TABLE 5: CATEGORY OF ATT
M F T %
Cat I 49 41 90 59
Cat II 10 4 14 9
Cat III 29 23 52 32
Eighty six patients were sputum positive (55%) out of which 56% were males and 
44% were females.
TABLE 6: BODY MASS INDEX (BMI)
BMI M F T %
<18.5 20 15 35 22.4
18-24.9 59 47 106 68
>25 10 5 15 9.6
MEAN 20.5
S.D 3.1
The  mean  BMI  was  20.5+3.1kg/m2.  Body  mass  index  was  <18.5kg/m2 in  35 
patients (22.4%).
The mean hemoglobin values were 10.4+1.8gms/dl. It was found that 49 patients 
(31.4%) had a hemoglobin level of <9.9grams/dl, signifying moderate to severe anemia.
TABLE 7: HEMOGLOBIN (Hb) LEVELS
Serum albumin levels  were < 3.5 grams/dl  in  37 patients  (23.7%).  The mean 
albumin values were 3.88+0.73grams/dl.
TABLE 8: SERUM ALBUMIN LEVELS
Albumin(grams/dl)
Cases
No. %
<  3.5 37 23.7
> 3.5 119 76.3
Mean
S.D.
3.88
0.73
Nineteen patients (12%) had systemic disease in the form of diabetes mellitus or 
chronic renal failure. 
Twenty two patients (14.1%) of patients tested positive for HIV. 
RESULTS OF LFT
Overall, 24 patients out of 156 had some abnormality of liver function (15.4%). 
The  most  common  form of  hepatotoxicity  was  asymptomatic  rise  in  transaminases 
(n=16) followed by acute hepatitis like picture with jaundice (n=8). All 16 patients who 
developed increase in enzymes were asymptomatic.
Eight patients developed jaundice. There was no incidence of fulminant hepatic 
failure or chronic hepatitis. All patients who developed liver injury were investigated for 
viral  hepatitis  and  none  of  the  patients  tested  positive  for  any  of  the  viral  markers 
performed  namely,  IgM  antibody  for  HAV,  HbSAg,  and  anti  HCV.  Most  of  the 
derangements  occurred  within  the  first  two  weeks  of  starting  therapy  and  subsided 
spontaneously on stopping the drug within 4-6 weeks. The results are summarized in 
tables 9, 10 and 11.
TABLE 9: BILIRUBIN ABNORMALITIES
Bilirubin at 
< 1.5mg% > 1.5mg%
Mean S.D.
No. % No. %
0 week 156 100 - - 0.81 0.19
2 weeks 150 94.9 6 5.1 1.01 0.37
4 weeks 154 98.7 2 1.3 0.85 0.19
24 weeks 156 100 - - 0.78 0.16
It was observed that the mean bilirubin levels were 1.01+0.37mg% in the second 
week and dropped down to 0.85+0.19mg% at the end of four weeks. Six patients had 
jaundice at the end of two weeks and two patients had persistent jaundice at four weeks 
that recovered within the next two weeks.
The abnormalities in liver enzymes were analyzed in relation to the time of onset 
of enzyme elevation. 
TABLE 10: ENZYME ABNORMALITIES
SGOT/SGPT at
NORMAL INCREASED
Mean S.D.
No. % No. %
0 week 156 100 - - 26.3 6.7
2 weeks 136 87.2 20 12.8 67.5 9.4
4 weeks 155 99.4 1 0.6 30.3 18.9
24 weeks 156 100 - - 26.3 6.3
It was observed that most of the enzyme abnormalities occurred within the 
first 2 weeks. Twenty patients (12.8%) developed enzyme elevation within two weeks 
of starting therapy and only one patient had persisting abnormality at the end of four 
weeks.
The patterns of hepatotoxicity were analyzed in relation to symptoms and LFT 
abnormality.
TABLE 11: PATTERN OF HEPATOTOXICITY
Age group Clinical 
hepatitis
Asymptomatic enzyme 
elevation
percentage
Male Female
<30 yrs 1 1 3 25%
30-39 0 2 0 8.3%
40-49 3 4 0 29.16%
50-59 2 0 3 16.66%
>60 2 0 3 20.8%
total 8 7 9
It was observed that asymptomatic enzyme elevation was the most common form 
of hepatotoxicity seen in 16 patients (66.6%) followed by clinical hepatitis with jaundice 
in eight patients (33.3%). There was near equal incidence of toxicity in males (n=7) and 
females (n=9).
The initial elevation in liver function tests is summarized in table 12.
TABLE 12: INITIAL ELEVATION OF LFTs
Weeks No of 
patients 
AST  ALT Bilirubin
0 166 - - -
1 166 - - -
2 159 14 14 6
4 156 2 2 2
8 156 - - -
24 156 - - -
Total 156 16 16 8
Values indicate number of patients.
                     Analysis of hepatotoxicity in relation to the various risk factor parameters  
was done and the following observations were made- 
1. Category of ATT  :  
 It was observed that six patients (42.9%) started on category II developed toxicity 
in comparison to 13 patients (14.4%) on category I and five patients (9.6 %) on category 
III.
TABLE 13: CATEGORY OF ATT VERSUS HEPATOTOXICITY
Category of ATT
LFT abnormality
Present Absent
No. % No. %
I (90) 13 14.4 77 85.6
II (14) 6 42.9 8 57.1
III (52) 5 9.6 47 90.4
2. Age group: 
It was observed that five out of 12 patients above the age of 60 years developed 
abnormalities of LFT (41.7%). 
TABLE 14: AGE AND HEPATOTOXICITY
The  value  was  statistically  significant  (p=0.0027), implying  that  the  elderly 
patients were more susceptible to liver damage due to ATT.
3. Sputum positivity:
 It was observed that out of 86 patients who were sputum positive, 19 developed 
hepatotoxicity (22.1%) in comparison with only five sputum negative patients (7.1%).
TABLE 15: SPUTUM POSITIVITY VERSUS HEPATOTOXICTY
Sputum
LFT abnormality
Present Absent
No. % No. %
Positive (86) 19 22.1 67 77.9
Negative (70) 5 7.1 65 92.9
‘p’ 0.0187
Significant
80% of  patients  with  hepatotoxicity  were  sputum positive,  possibly  indicating 
severe disease as a risk factor for hepatotoxicity. The value was statistically significant 
(p=0.0187).
4. Hemoglobin  :  
Out of 49 patients who had moderate to severe anemia, 17 developed liver injury 
(34.7%). In contrast, only seven patients who had hemoglobin levels above 9.9grams% 
developed toxicity (6.5%).
TABLE 16: ANEMIA VERSUS HEPATOTOXICTY
70% of patients with toxicity had hemoglobin levels <9.9gm% and the value was 
statistically significant  (p=0.0001).  Moderate to severe anemia directly correlated with 
hepatotoxicity.
5. Body mass index: 
It was observed that 19 out of 35 patients (54.3%) with BMI <18.5kg/m2 had LFT 
abnormalities.
TABLE 17: MALNUTRITION AND HEPATOTOXICITY
BMI (kg/m2)
LFT abnormality
Present Absent
No. % No. %
< 18.5 (35) 19 54.3 16 45.7
> 18.5 (121) 5 4.1 116 95.9
Mean
S.D.
17.13
1.39
21.09
2.9
‘p’ 0.0001
Significant
80% of patients with toxicity had BMI values of <18.5kg/m2  and the value was 
statistically significant (p=0.0001), implying that malnutrition may be a significant risk 
factor for toxicity.
6. Serum albumin: 
It was observed that 45.9% of patients with hypoalbuminemia (n=17) had toxicity. 
The value was statistically significant (p=0.0001) as shown in the table below.
TABLE 18: HYPOALBUMINEMIA AND HEPATOTOXICITY
Serum albumin 
(grams/dl)
LFT abnormality
Present Absent
No. % No. %
<  3.5 (37) 17 45.9 20 54.1
>  3.5 (119) 7 5.9 112 94.1
Mean
S.D.
3.14
0.84
4.01
0.61
‘p’ 0.0001
Significant
7. HIV status: 
Out  of  22  patients  who  tested  positive  for  HIV,  11  (50%)  developed 
hepatotoxicity. 
TABLE 19: HIV STATUS AND HEPATOTOXICITY
HIV
LFT abnormality
Present Absent
No. % No. %
Positive (22) 11 50 11 50
Negative (134) 13 9.7 121 90.3
‘p’ 0.0001
Significant
The value obtained was statistically significant  (p=0.0001)  indicating that HIV 
infection may be a significant risk factor for ATT induced hepatotoxicity.
8. Site of disease  : 
 Hepatotoxicity  was  more  in  abdominal  (25%)  and  pulmonary  tuberculosis 
(22.2%) that in other types of tuberculosis.
TABLE 20: SITE OF DISEASE AND HEPATOTOXICITY
Site of disease
LFT abnormality
Present Absent
No. % No. %
AB (4) 1 25 3 75
LN (13) - - 13 100
P (90) 20 22.2 70 77.8
PE (31) 3 9.7 28 90.3
SK (2) - - 2 100
TBM (16) - - 16 100
DISCUSSION
The wide prevalence of tuberculosis through out the world makes it a social and 
economical burden especially for developing countries and the use of anti tuberculous 
drugs  is  an  optimistic  approach  for  this  problem.  However  certain  reservations 
associated with its use need to be properly evaluated especially ATT induced liver injury 
and the predisposing factors that add to this hepatotoxicity.
This study was conducted to study the incidence of ATT induced hepatotoxicity in 
RNTCP clinic,  Madurai  and  to  assess  the  role  of  age,  sex,  severity  of  the  disease, 
nutritional status, hypoalbuminemia, sputum positivity and HIV status as risk factor for 
ATT induced hepatotoxicity. 
The  reported  incidence  of  ATT induced  hepatotoxicity  is  different  in  various 
countries though not fully understood but could be due to the characteristics and the risk 
factors  of  the  population  studied,  the  different  diagnostic  criteria  used  to  define 
hepatotoxicity, different geographical areas, tests carried out during follow ups and the 
type of monitoring.25 
Why only some patients who receive ATT develop hepatitis is not clear 
and several studies searched for host factors, environmental factors or some 
interaction among various factors. While some papers have focused on genetic factors, 
such as HLA typing, Cytochrome P450 2E1 or acetylator status, others have primarily 
studied clinical factors.
In this study of 156 patients, all were administered DOTS therapy under RNTCP 
and belonged to different treatment categories.  Male: female ratio was almost equal 
(53.5%:48.5%). Age group of the patients ranged from 15-78 years. 
Various  studies  report  different  incidence  rates  of  hepatotoxicity  due  to  anti 
tuberculous therapy. A higher risk of hepatotoxicity has been reported in Indian patients 
than in their Western counterparts.19, 26 the risk of hepatotoxicity based on data from four 
prospective Indian studies was 11.5% compared with 4.3% in Western publications.15 
In our study 15.4% of the patients developed ATT induced hepatotoxicity that almost 
overlaps the other studies conducted world wide. The incidence of hepatotoxicity due to 
combination chemotherapy ranges from 1-39%. The following is a list of incidence by 
some workers:
1. Parthasarathy et al 27 TBM: 16-39%, PT: 2-3%
2. Schberg et al 9 11%
3. Devoto et al 21 9.9%
4. Steele et al 15 2.6%
5. Dossing et al 10 8%
6. Kamat et al28 18%
7. Sivaraman et al29 7%
8. Our study 15.4%
The  TRC,  Chennai  published  its  first  report  on  hepatotoxicity  induced  by 
antituberculous drug therapy and the incidence was 2.5%.
 In  a  study  done  in  Pakistan,  19.76%  of  the  patients  developed  ATT  induced 
hepatotoxicity  that  almost  overlapped  the  study  conducted  at  Japan.30,31  A  study 
conducted in Nepal32  resulted in 8% and 13% in Hong Kong Chinese patients.33 In the 
analysis done by Col AC Anand et al, the incidence of hepatotoxicity among patients on 
ATT was 10.1%,34 
In  our  study  we  analyzed  the  possible  predisposing  factors  for  hepatotoxicity 
induced  ATT.  A significant  proportion  of  patients  older  than  60  years  developed 
hepatotoxicity (p=0.0027). Although the number of patients above the age of 60 years 
receiving ATT was less (n=12), nearly half of these patients developed liver function 
abnormalities. 
Some studies have reported that the risk of ATT-induced hepatitis increases with 
advancing age, the highest incidence being in individuals older than 50 years as shown 
by Gangadharan et al.35 
In a study done by Col AC Anand et al in 2006, no significant correlation of age 
with ATT-induced hepatotoxicity was found. However, once hepatotoxicity developed, 
fatal out come was much more likely among the older patients (mean age 47.1 years as 
compared to 38.9 years in non fatal cases).34 Studies from Pande et al and other workers 
showed that increasing age is associated with more hepatotoxicity.20, 36, 37 
 In a study done by Khalid Mohammad et al, older age group was affected more as 
compared to younger one (25.8% vs. 14.4%).30 
 Although previous studies have quoted an increased risk of hepatotoxicity for 
females, it was found to be almost equal in this study. There was a marginal increase in 
sub clinical hepatitis in females in accordance with many other studies (nine in females 
vs.  seven  in  males). Vulnerability  of  females  could  be  due  to  variations  in 
pharmacokinetics and slow acetylating enzymatic pattern, resulting in hepatotoxicity.20, 38 
Anand AC et al did not find any difference in the incidence of hepatotoxicity in 
their study.34 This has also been reported in a study done by Taneja et al.39
 Nutritional status of our patients was very poor. BMI were below 18.5 (kg/m2) in 
23% of patients and 23.4% of the patients had hypoalbuminemia. In our study there was 
a significant relationship of hepatotoxicity to low serum albumin and low BMI as noted 
in the previous studies done by Pande et al20. Nearly 72% of patients with hepatotoxicity 
had serum albumin <3.5 grams%. 
Krishnasamy says  that  under  nutrition  contributes  to  drug toxicity  by  various 
mechanisms. 40,  41   Toxicity and over dosage is much more likely to occur even with 
normal dosage of medicine in the presence of normal serum albumin.42 A study from 
Pakistan shows significant correlation between the two variables.30 
The  possible  explanation  of  ATT  induced  hepatotoxicity  in  malnutrition  is 
depletion of  glutathione stores that  makes one vulnerable  to oxidative injuries.  Low 
nutritional status is considered to be one of the factors contributing to relatively high 
incidence  of  ATT-related  hepatitis  in  studies  from  developing  countries.  Drug 
metabolism pathways including acetylation pathway have been shown to be deranged in 
states of protein energy malnutrition.43, 44 
A direct  correlation  was  also  obtained  between  low  BMI  and  hepatotoxicity 
(p=0.0001) and this was in concordance with the previous studies done by Shakya et al.7 
A  similar  significant  relationship  was  noted  between  hemoglobin  levels  and 
hepatotoxicity (p=0.0001). Most of the patients with hepatotoxicity had severe anemia. 
Nineteen  patients  (80%)  were  sputum smear  positive  and  they  were  severely 
affected indicating the extensiveness of  the disease also as a risk factor  as  noted in 
previous studies done by Pande et al20 (p=0.001)and Devoto et al 21(p=0.02). Severity of 
the disease in sputum smear positive patients could be secondary to more tubercular 
bacilli in smear positive patients as compared to smear negative patients. 
In  our  study,  there  was  direct  association  between  sputum  positivity  and 
hepatotoxicity  (p=0.0187).  In  the  study  done  by  Khalid  Mohammad,  forty  patients 
(59.70%) were sputum smear positive and they were severely affected indicating the 
extensiveness of the disease as a risk factor.30, 45, 10, 20 
In our study, HIV infection was found to be a significant risk factor for TB DILI 
(p=0.0001).  The patients  were not  on antiretroviral  therapy at  the start  of ATT, thus 
ruling out antiretroviral therapy as the cause of liver function abnormalities. This was in 
concordance with the previous studies done by the European tuberculosis study group 
where it was found that patients with HIV and TB had significant risk of hepatotoxicity 
irrespective of whether the patient was on ART or not.16 
None  of  the  patients  in  this  study  who developed  toxicity  had  viral  hepatitis 
though there is evidence to indicate that patients with viral hepatitis B  or hepatitis C had 
a higher risk of drug toxicity than general population.46, 47, 48
The frequency of self limiting asymptomatic enzyme elevation raises the question of 
whether the drugs should be stopped; and if so, at what levels they should be stopped. 
Mild transient self limiting transaminase rise occurs early during the course of therapy 
irrespective of the regimen used and this should not be used as a criterion for stopping 
therapy. Onset of hepatotoxicity occurred within one month of start of therapy in our 
study. Usually pyrazinamide produced a delayed onset of hepatotoxicity whereas early 
toxicity is produced by isoniazid and rifampicin.
Parthasarathy et al concluded that acute hepatitis is nearly always associated with 
jaundice.27 In our study also, patients who developed jaundice has an enzyme elevation 
of >200 IU/L. after withdrawing the drugs, all  levels returned to normal within four 
weeks. 
Some workers say it may not be advisable to stop all drugs at a time but since the 
possibility of fulminant hepatic failure always arises, it is advisable to stop all drugs till  
enzyme  elevation  settles  down  to  normal  levels.  In  our  study,  all  drugs  were 
reintroduced according to the British Thoracic society guidelines24. None of the patients 
developed recurrent hepatotoxicity.
The  onset  of  drug  induced  hepatotoxicity  cannot  be  exactly  predicted  but 
measures to prevent it can be taken well in advance. High protein diet, abstinence from 
alcohol and smoking, good supportive medications like vitamin B6 and vitamin C have 
shown to reduce the incidence of  hepatotoxicity.  Well  educated patients  and skilled, 
alert,  treatment  supervisor  can  reduce  the  hepatotoxicity,  fulminant  hepatitis  and  its 
complications.  
SUMMARY
In this  study,  156 patients  belonging to  different  categories of  RNTCP-DOTS 
were followed up for a period of six months. There were 88 Males and 68 females. 
15.4%  of  patients  developed  liver  function  abnormalities  of  which  asymptomatic 
enzyme elevation was the most common feature. There was no incidence of fulminant 
hepatic failure or chronic hepatitis.
Transient self limiting rise of transaminases occurred early during the course of 
therapy  which  subsided  on  stopping  drug  over  a  period  of  four  to  six  weeks. 
Reintroduction of ATT was tolerated well and all had completed treatment. Advancing 
age,  malnutrition,  anemia,  advanced disease with sputum positivity,  hypoproteinemia 
and HIV positivity directly correlated with drug induced hepatotoxicity. 
Identification of these risk factors may be helpful in predicting hepatotoxicity and 
correction  of  the  modifiable  risk  factors  prior  to  start  of  therapy  may  prevent  liver 
damage.
CONCLUSIONS
     The following conclusions were made from our study-
1. Liver function abnormalities occurred in 15% of the study group under  
 RNTCP which is a significant number.
2.  Asymptomatic  enzyme  elevation  is  the  most  common  abnormality  in 
our study.
 3. Direct correlation existed between increasing ages, malnutrition,   anaemia, advanced 
disease with sputum positivity and hypoproteinemia.
Correction of the modifiable risk factors can lead to decrease in hepatotoxicity.
4.  Hepatotoxicity  is  usually  self  limiting  and  treatment  need  not  be  discontinued 
permanently.
5.  Serial  monitoring  of  liver  function  tests  will  help  in  early  identification  of  drug 
induced hepatotoxicity and prevention of fulminant hepatic failure.
6. Further research is needed to find out the exact mechanisms of  hepatotoxicity due to 
ATT and the possible role of hepatoprotective agents.
FIGURE 1
Illustration of the proposed mechanism of DILI, which involves drug metabolism, 
hepatocyte damage, activation of innate immune cells, and production of tissue-
damaging  and  tissue-protective  mediators.  CYP  -  cytochrome  P450;   IFN- 
interferon; IL- interleukin; NK-natural killer cell; NKT- natural killer T cell;  TNF- 
tumor necrosis factor.
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FIGURE 5: SGOT ABNORMALITIES
FIGURE 6: CATEGORY OF ATT VERSUS HEPATOTOXICITY
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FIGURE 7: AGE VERSUS HEPATOTOXICITY
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FIGURE 8: SPUTUM POSITIVITY VERSUS HEPATOTOXICITY
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FIGURE 9: ANEMIA VERSUS HEPATOTOXICITY
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FIGURE 10: MALNUTRITION VERSUS HEPATOTOXICITY
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FIGURE 11: HYPOALBUMINEMIA VERSUS HEPATOTOXICITY
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FIGURE 12: HIV STATUS VERSUS HEPATOTOXICITY
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PROFORMA
S.NO
NAME:                                AGE:                  SEX: M/F
ADDRESS:        IP/OP NO.:
DIAGNOSIS: P/PE/LN/TBM/AB/SK RNTCP CATEGORY: I
             II
            III
SPUTUM +/-
DATE OF STARTING ATT:
SYMPTOMS ONSET DURATION
ANOREXIA
NAUSEA
VOMITING
JAUNDICE
BLEEDING
FEVER
JOINT PAIN
CLAY STOOLS
RASH
EPIGASTRIC PAIN
CLINICAL EXAMINATION
WEIGHT HEIGHT
BMI ANEMIA
JAUNDICE HEPATOMEGALY
RIGHT HYPOCHONDRIAL TENDERNESS
SKIN RASH
ARTHRITIS BLEEDING
INVESTIGATIONS
HEMOGLOBIN IgM Anti HAV
TOTAL WBC COUNT HBsAg
DIFFERNTIAL COUNT AntiHCV
PERIPHERAL SMEAR
URINE BILE SALTS
URINE BILE PIGMENTS
URINE ALBUMIN
CHEST X RAY PA VIEW
HIV ELISA
ULTRASONOGRAM ABDOMEN
LIVER FUNCTION TESTS:
PARAMETER WEEK
0 1 2 4 8 24
S.BILIRUBIN
TOTAL
DIRECT
INDIRECT
SGOT
SGPT
ALP
S.PROTEINS
TOTAL
ALBUMIN
GLOBULIN
KEY TO MASTER CHART
PT ID - patient identification
BMI - body mass index
HB - hemoglobin
AST - aspartate transaminase
ALT - alanine transaminase
HIV - human immunodeficiency virus
P - Pulmonary
PE - pleural effusion
AB - abdominal
TBM - tuberculous meningitis
SK - skeletal
LN - lymph node
m - Male
f- Female
dm – diabetes mellitus
crf – chronic renal failure
+ Positive
- Negative
ABBREVIATIONS 
AB – Abdominal
AIDS – Acquired Immuno Deficiency Syndrome
AIIMS - All India Institute of Medical Sciences
ART – Anti Retroviral Therapy
CSF – Cerebrospinal fluid
DOTS – Directly Observed Treatment Short Course
HAV - Hepatitis A virus
HBeAg – Hepatitis B e Antigen
HBsAg – Hepatitis B surface Antigen
HCV – Hepatitis C virus
HIV - Human Immunodeficiency Virus
HLA – Human Leucocyte Antigen
IFN – Interferon
INH – Isoniazid
LFT – Liver Function Tests
LN – Lymph node 
MDR – Multi Drug Resistant
P – Pulmonary
PE – Pleural effusion
SGOT – Serum Glutamate Oxaloacetate Transaminase
SGPT – Serum Glutamate Pyruvate Transaminase
SK – Skeletal
TB – Tuberculosis
TBM – Tuberculous meningitis
TRC - Tuberculosis Research Center
ULN – Upper Limit of Normal
WHO - World Health Organization
